B. Mouillac

发表

Time-resolved FRET between GPCR ligands reveals oligomers in native tissues.

J. Javitch, J. Pin, I. Brabet, 2010, Nature chemical biology.

Distinct roles of metabotropic glutamate receptor dimerization in agonist activation and G-protein coupling

J. Pin, B. Mouillac, R. Rahmeh, 2012, Proceedings of the National Academy of Sciences.

Green mamba peptide targets type-2 vasopressin receptor against polycystic kidney disease

E. De Pauw, J. Tytgat, G. Mourier, 2017, Proceedings of the National Academy of Sciences.

Oxytocin and vasopressin V1a and V2 receptors form constitutive homo- and heterodimers during biosynthesis.

B. Mouillac, T. Durroux, R. Jockers, 2003, Molecular endocrinology.

Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands.

L. Albizu, R. Seyer, H. Bazin, 2007, Journal of medicinal chemistry.

Agonist-modulated palmitoylation of beta 2-adrenergic receptor in Sf9 cells.

M. Caron, B. Mouillac, M. Bouvier, 1992, The Journal of biological chemistry.

Crosslinking photosensitized by a ruthenium chelate as a tool for labeling and topographical studies of G-protein-coupled receptors.

B. Mouillac, E. Richard, J. Guichou, 2005, Chemistry & biology.

The Concise Guide to Pharmacology 2013/14: Overview

Adam J Pawson, Stephen P. H. Alexander, A. A. Khan, 2013, British journal of pharmacology.

The D136A mutation of the V2 vasopressin receptor induces a constitutive activity which permits discrimination between antagonists with partial agonist and inverse agonist activities

N. Cotte, C. Breton, M. Manning, 1998, FEBS letters.

Heterodimerization with Its Splice Variant Blocks the Ghrelin Receptor 1a in a Non-signaling Conformation

B. Mouillac, Jean Martinez, J. Fehrentz, 2013, The Journal of Biological Chemistry.

Vasopressin receptors and pharmacological chaperones: from functional rescue to promising therapeutic strategies.

B. Mouillac, C. Mendre, 2014, Pharmacological research.

Past, present and future of vasopressin and oxytocin receptor oligomers, prototypical GPCR models to study dimerization processes.

L. Albizu, M. Cottet, B. Mouillac, 2010, Current opinion in pharmacology.

Palmitoylated Cysteine 341 Modulates Phosphorylation of the β2-Adrenergic Receptor by the cAMP-dependent Protein Kinase*

B. Mouillac, M. Bouvier, H. Bonin, 1996, The Journal of Biological Chemistry.

Biased Agonist Pharmacochaperones: Small Molecules in the Toolbox for Selectively Modulating GPCR Activity

B. Mouillac, C. Mendre, 2017 .

Misfolding of vasopressin receptors: biased agonist pharmacochaperones as potential therapeutics.

B. Mouillac, C. Mendre, 2019, Advances in protein chemistry and structural biology.

Pharmacological Chaperones as Potential Therapeutic Strategies for Misfolded Mutant Vasopressin Receptors.

B. Mouillac, C. Mendre, 2018, Handbook of experimental pharmacology.

Functional studies of twelve mutant V2 vasopressin receptors related to nephrogenic diabetes insipidus: molecular basis of a mild clinical phenotype.

N. Cotte, C. Antignac, G. Alonso, 1998, Journal of the American Society of Nephrology : JASN.

A snake toxin as a theranostic agent for the type 2 vasopressin receptor

B. Jego, G. Mourier, D. Servent, 2020, Theranostics.

Altered phosphorylation and desensitization patterns of a human beta 2‐adrenergic receptor lacking the palmitoylated Cys341.

B. Mouillac, M. Bouvier, H. Bonin, 1993, The EMBO journal.

Subtlety of the structure-affinity and structure-efficacy relationships around a nonpeptide oxytocin receptor agonist.

B. Mouillac, T. Durroux, M. Hibert, 2010, Journal of medicinal chemistry.

Solid-phase organic tagging resins for labeling biomolecules by 1,3-dipolar cycloaddition: application to the synthesis of a fluorescent non-peptidic vasopressin receptor ligand.

B. Mouillac, R. Rahmeh, J. Haiech, 2008, Chemistry.

Synthesis and Characterization of Fluorescent Antagonists and Agonists for Human Oxytocin and Vasopressin V1a Receptors

S. Stoev, M. Manning, B. Mouillac, 2002 .

Identification of the Binding Sites of the SR49059 Nonpeptide Antagonist into the V1a Vasopressin Receptor Using Sulfydryl-reactive Ligands and Cysteine Mutants as Chemical Sensors*

Didier Rognan, Marcel Hibert, D. Rognan, 2003, Journal of Biological Chemistry.

Selective fluorescent nonpeptidic antagonists for vasopressin V₂ GPCR: application to ligand screening and oligomerization assays.

Esther Kellenberger, Eric Trinquet, Marcel Hibert, 2012, Journal of medicinal chemistry.

Structure of the antidiuretic hormone vasopressin receptor signalling complex

Rémy Sounier, S. Trapani, C. Leyrat, 2020, bioRxiv.

Time resolved FRET strategy with fluorescent ligands to analyze receptor interactions in native tissues: application to GPCR oligomerization.

J. Pin, L. Albizu, M. Cottet, 2011, Methods in molecular biology.

Vasopressin-Oxytocin Receptors*

B. Mouillac, C. Barberis, 2008 .

V-1A Vasopressin Receptor

B. Mouillac, C. Barberis, 2008 .

OT Oxytocin Receptor

B. Mouillac, C. Barberis, 2008 .

Genomic and non-genomic mechanisms of oxytocin receptor regulation.

G. Guillon, C. Breton, B. Mouillac, 1998, Advances in experimental medicine and biology.

Efficient photoaffinity labeling of the rat V1a vasopressin receptor using a linear azidopeptidic antagonist.

G. Guillon, R. Seyer, B. Mouillac, 1997, European journal of biochemistry.

Expression, purification and NMR characterization of the cyclic recombinant form of the third intracellular loop of the vasopressin type 2 receptor.

B. Mouillac, S. Urbach, G. Bellot, 2011, Protein expression and purification.

Mammalian membrane receptors expression as inclusion bodies in Escherichia coli.

B. Mouillac, J. Banères, 2010, Methods in molecular biology.

Structure of the third intracellular loop of the vasopressin V2 receptor and conformational changes upon binding to gC1qR.

R. Seyer, B. Mouillac, R. Rahmeh, 2009, Journal of molecular biology.

A new Kunitz‐type snake toxin family associated with an original mode of interaction with the vasopressin 2 receptor

E. De Pauw, G. Mourier, D. Servent, 2021, British journal of pharmacology.

Identification of Residues Responsible for the Selective Binding of Peptide Antagonists and Agonists in the V2 Vasopressin Receptor*

N. Cotte, M. Manning, B. Mouillac, 1998, The Journal of Biological Chemistry.

Mechanisms of phospholipase C activation: a comparison with the adenylate cyclase system.

B. Mouillac, M. Balestre, C. Kirk, 1987, Biochimie.

The multifunctional protein GC1q-R interacts specifically with the i3 loop arginine cluster of the vasopressin V2 receptor

G. Guillon, B. Mouillac, S. Granier, 2008, Regulatory Peptides.

Heterodimerization with its splice variant blocks the ghrelin receptor 1a in a nonsignaling conformation. A study with a purified heterodimer assembled into lipid discs.*

B. Mouillac, Jean Martinez, J. Fehrentz, 2013 .

The Constitutively Active V2 Receptor Mutants Conferring NSIAD Are Weakly Sensitive to Agonist and Antagonist Regulation

B. Ranchin, B. Mouillac, T. Durroux, 2009, PloS one.

Dual mechanisms of inhibition by dopamine of basal and thyrotropin-releasing hormone-stimulated inositol phosphate production in anterior pituitary cells. Evidence for an inhibition not mediated by voltage-dependent Ca2+ channels.

J. Bockaert, B. Mouillac, V. Audinot, 1990, The Journal of biological chemistry.

Pharmacological characterization of inositol 1,4,5-trisphosphate binding sites: relation to Ca2+ release.

G. Guillon, B. Mouillac, S. Jard, 1992, European journal of pharmacology.

Design, synthesis and pharmacological characterization of a potent radioiodinated and photoactivatable peptidic oxytocin antagonist.

R. Seyer, C. Breton, B. Mouillac, 2001, Journal of medicinal chemistry.

Dynamic palmitoylation of G-protein-coupled receptors in eukaryotic cells.

B. Mouillac, P. Chidiac, M. Bouvier, 1995, Methods in enzymology.

Modulation of hormone-sensitive phospholipase C.

B. Mouillac, G. Guillon, A. Savage, 1992, Cellular signalling.

Transient inositol (1,4,5) trisphosphate accumulation under vasopressin stimulation in WRK1 cells: correlation with intracellular calcium mobilization.

B. Mouillac, M. Balestre, G. Guillon, 1989, Biochemical and biophysical research communications.

Properties of membranous phospholipase C from WRK1 cell: sensitivity to guanylnucleotides and bacterial toxins.

B. Mouillac, M. Balestre, C. Lombard, 1989, Cellular signalling.

Properties of a new radioiodinated antagonist for human vasopressin V2 and V1a receptors.

N. Cotte, E. Tribollet, J. Dreifuss, 1997, European journal of pharmacology.

THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Overview

Arthur Christopoulos, Christopher Southan, Stephen PH Alexander, 2017, British journal of pharmacology.

Differential Coupling of the Vasopressin V1b Receptor through Compartmentalization within the Plasma Membrane

L. Albizu, B. Mouillac, T. Durroux, 2009, Molecular Pharmacology.

Amphipols in G Protein-Coupled Receptor Pharmacology: What Are They Good For?

B. Mouillac, R. Rahmeh, S. Granier, 2014, The Journal of Membrane Biology.

Palmitoylation of G-protein-coupled receptors: a dynamic modification with functional consequences.

B. Mouillac, P. Chidiac, M. Bouvier, 1995, Biochemical Society transactions.

THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors

Stephen P. H. Alexander, Leigh A. Stoddart, Kalyan C. Tirupula, 2021, British journal of pharmacology.

Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.

G. Guillon, S. Stoev, M. Manning, 2008, Progress in brain research.

LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism.

B. Mouillac, T. Durroux, D. Bonnet, 2018, Journal of medicinal chemistry.

Oxytocin and Vasopressin Agonists and Antagonists as Research Tools and Potential Therapeutics

G. Guillon, S. Stoev, M. Manning, 2012, Journal of neuroendocrinology.

Mapping Peptide-binding Domains of the Human V1a Vasopressin Receptor with a Photoactivatable Linear Peptide Antagonist*

N. Cotte, E. Mahé, R. Seyer, 1997, The Journal of Biological Chemistry.

Design, synthesis and biological studies of a library of NK1-Receptor Ligands Based on a 5-arylthiosubstituted 2-amino-4,6-diaryl-3-cyano-4H-pyran core: Switch from antagonist to agonist effect by chemical modification.

B. Mouillac, E. Álvarez, H. Orcel, 2017, European journal of medicinal chemistry.

Design of benzophenone-containing photoactivatable linear vasopressin antagonists: pharmacological and photoreactive properties.

R. Seyer, B. Mouillac, C. Barberis, 2005, Journal of medicinal chemistry.

Vasopressin and oxytocin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

G. Gimpl, J. Verbalis, D. Bichet, 2019, IUPHAR/BPS Guide to Pharmacology CITE.

The Binding Site of Neuropeptide Vasopressin V1a Receptor

J Hoflack, S. Trumpp-Kallmeyer, B. Mouillac, 1995, The Journal of Biological Chemistry.

Inhibition of oxytocin receptor function by direct binding of progesterone

Hans H. Zingg, G. Guillon, B. Mouillac, 1998, Nature.

Structural bases of vasopressin/oxytocin receptor function.

B. Mouillac, T. Durroux, C. Barberis, 1998, The Journal of endocrinology.

Design of peptide oxytocin antagonists with strikingly higher affinities and selectivities for the human oxytocin receptor than atosiban

S. Stoev, M. Manning, B. Mouillac, 2005, Journal of peptide science : an official publication of the European Peptide Society.

Carbohydrate-Based NK1R Antagonists with Broad-Spectrum Anticancer Activity

B. Mouillac, M. López-Lázaro, J. A. Organero, 2021, Journal of medicinal chemistry.

Structural insights into biased G protein-coupled receptor signaling revealed by fluorescence spectroscopy

Eric Trinquet, Bernard Pucci, Sébastien Granier, 2012, Proceedings of the National Academy of Sciences.

New advances in production and functional folding of G-protein-coupled receptors.

J. Popot, B. Mouillac, J. Banères, 2011, Trends in biotechnology.

Leukotriene BLT2 Receptor Monomers Activate the Gi2 GTP-binding Protein More Efficiently than Dimers*

Sébastien Granier, B. Mouillac, T. Durroux, 2009, The Journal of Biological Chemistry.

Tyr115 is the key residue for determining agonist selectivity in the V1a vasopressin receptor.

J Hoflack, S. Trumpp-Kallmeyer, M. Manning, 1995, The EMBO journal.

Molecular pharmacology of AVP and OT receptors and therapeutic potential

E. Tribollet, G. Guillon, R. Seyer, 1999 .

[Pharmacological chaperones: a potential therapeutic treatment for conformational diseases].

B. Mouillac, C. Mendre, 2010, Medecine sciences : M/S.

V1b vasopressin receptor trafficking and signaling: Role of arrestins, G proteins and Src kinase

B. Mouillac, T. Durroux, M. Corbani, 2018, Traffic.

Fluorescent ligands to investigate GPCR binding properties and oligomerization.

J. Pin, M. Cottet, E. Trinquet, 2013, Biochemical Society transactions.

Two aromatic residues regulate the response of the human oxytocin receptor to the partial agonist arginine vasopressin

S. Trumpp-Kallmeyer, B. Mouillac, J. Hoflack, 1996, FEBS letters.

Desensitization, phosphorylation and palmitoylation of the human dopamine D1 receptor.

M. Caron, B. O'dowd, S. George, 1994, European journal of pharmacology.

The ligand-bound state of a G protein-coupled receptor stabilizes the interaction of functional cholesterol molecules

V. Cherezov, F. Rébeillé, C. Domene, 2021, Journal of lipid research.

Activation of polyphosphoinositide phospholipase C by fluoride in WRK1 cell membranes

G. Guillon, B. Mouillac, M. Balestre, 1986, FEBS letters.

Fluorescent agonists and antagonists for vasopressin/oxytocin G protein-coupled receptors: usefulness in ligand screening assays and receptor studies.

M. Manning, B. Mouillac, T. Durroux, 2008, Mini reviews in medicinal chemistry.

Fluorescent-Based Strategies to Investigate G Protein-Coupled Receptors: Evolution of the Techniques to a Better Understanding

J. Pin, B. Mouillac, T. Durroux, 2017 .

Cryo–electron microscopy structure of the antidiuretic hormone arginine-vasopressin V2 receptor signaling complex

Rémy Sounier, S. Trapani, C. Leyrat, 2021, Science Advances.

Towards understanding the role of the first extracellular loop for the binding of peptide hormones to G-protein coupled receptors.

S. Trumpp-Kallmeyer, B. Mouillac, J. Hoflack, 1995, Pharmaceutica acta Helvetiae.

Unusual signaling pathway of steroid hormones: Dual action of progesterone

J. Lehmann, S. Kliewer, T. Perlmann, 1999 .

Expression of human vasopressin and oxytocin receptors in Escherichia coli.

B. Mouillac, T. Durroux, C. Barberis, 2002, Progress in brain research.

Conserved aromatic residues in the transmembrane region VI of the V1a vasopressin receptor differentiate agonist vs. antagonist ligand binding.

N. Cotte, E. Mahé, M. Manning, 2000, European journal of biochemistry.

Cloning, expression and pharmacological characterization of a vasopressin-related receptor in an annelid, the leech Theromyzon tessulatum.

D. Vieau, C. Breton, B. Mouillac, 2005, The Journal of endocrinology.

Quantitative MALDI‐MS Binding Assays: An Alternative to Radiolabeling

C. Enjalbal, S. Cantel, Jean Martínez, 2016, ChemMedChem.

Activation of membrane phospholipase C by vasopressin

G. Guillon, B. Mouillac, M. Balestre, 1986, FEBS letters.

Functional Rescue of a Nephrogenic Diabetes Insipidus Causing Mutation in the V2 Vasopressin Receptor by Specific Antagonist and Agonist Pharmacochaperones

L. Hunyady, M. Toth, B. Mouillac, 2022, Frontiers in Pharmacology.

Vasopressin and oxytocin receptors in GtoPdb v.2023.1

G. Gimpl, J. Verbalis, D. Bichet, 2023, IUPHAR/BPS Guide to Pharmacology CITE.

TR-FRET Between Engineered Nanobodies Reveals Existence of Endogenous CXCR4 Oligomers

L. Lamarque, E. Trinquet, B. Mouillac, 2021, Social Science Research Network.

Ghrelin receptor conformational dynamics regulate the transition from a preassembled to an active receptor:Gq complex

D. Pérahia, E. Trinquet, B. Mouillac, 2015, Proceedings of the National Academy of Sciences.

Red Fluorescent Turn‐On Ligands for Imaging and Quantifying G Protein‐Coupled Receptors in Living Cells

Y. Mély, B. Mouillac, A. Klymchenko, 2014, Chembiochem : a European journal of chemical biology.

Influence of receptor density on the patterns of β2-adrenoceptor desensitization

G. Rousseau, B. Mouillac, P. Chidiac, 1997 .

Three-dimensional structure of G protein-coupled receptors: from speculations to facts

S. Trumpp-Kallmeyer, B. Mouillac, J. Hoflack, 1996 .

Bringing GPCR Structural Biology to Medical Applications: Insights from Both V2 Vasopressin and Mu-Opioid Receptors

Rémy Sounier, B. Mouillac, S. Granier, 2023, Membranes.

Structure of the vasopressin hormone–V2 receptor–β-arrestin1 ternary complex

Rémy Sounier, S. Trapani, N. Sibille, 2022, bioRxiv.

Functional architecture of vasopressin/oxytocin receptors.

J Hoflack, N. Cotte, S. Trumpp-Kallmeyer, 1999, Journal of receptor and signal transduction research.

Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors.

S. Stoev, M. Manning, B. Mouillac, 2002, Journal of medicinal chemistry.

Multicolor time‐resolved Förster resonance energy transfer microscopy reveals the impact of GPCR oligomerization on internalization processes

Eric Trinquet, Orestis Faklaris, J. Pin, 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Docking of linear peptide antagonists into the human V(1a) vasopressin receptor. Identification of binding domains by photoaffinity labeling.

N. Cotte, R. Seyer, C. Breton, 1999, The Journal of biological chemistry.

Biased agonist pharmacochaperones of the AVP V2 receptor may treat congenital nephrogenic diabetes insipidus.

Marcel Hibert, Marie-Céline Frantz, B. Mouillac, 2009, Journal of the American Society of Nephrology : JASN.

Probing the Existence of G Protein-Coupled Receptor Dimers by Positive and Negative Ligand-Dependent Cooperative Binding

Maurice Manning, Christophe Breton, J. Pin, 2006, Molecular Pharmacology.

Direct Identification of Human Oxytocin Receptor-binding Domains Using a Photoactivatable Cyclic Peptide Antagonist

R. Seyer, C. Breton, B. Mouillac, 2001, The Journal of Biological Chemistry.

Cloning , expression and pharmacological characterization of a vasopressin-related receptor in an annelid , the leech Theromyzon

D. Vieau, C. Breton, B. Mouillac, 2004 .

The two NK-1 binding sites correspond to distinct, independent, and non-interconvertible receptor conformational states as confirmed by plasmon-waveguide resonance spectroscopy.

I. Alves, Z. Salamon, G. Tollin, 2006, Biochemistry.

Positive feedback regulation of phospholipase C by vasopressin-induced calcium mobilization in WRK1 cells.

G. Guillon, B. Mouillac, M. Balestre, 1990, Cellular signalling.

Time-Resolved FRET-Based Assays to Characterize G Protein-Coupled Receptor Hetero-oligomer Pharmacology.

J. Pin, E. Trinquet, B. Mouillac, 2019, Methods in molecular biology.

Calcium regulation of hormonal-sensitive phospholipase C.

B. Mouillac, G. Guillon, J. Ibarrondo, 1991, Zeitschrift für Kardiologie.

Heterodimerization with Its Splice Variant Blocks the Ghrelin Receptor 1a in a Non-signaling Conformation

B. Mouillac, S. Mary, Marjorie Damian, 2021 .

Solid-phase organic tagging resins for labeling biomolecules by 1,3-dipolar cycloaddition: application to the synthesis of a fluorescent non-peptidic vasopressin receptor ligand.

B. Mouillac, J. Haiech, D. Bonnet, 2008, Chemistry.

Identification of a Single Residue Responsible for Agonist Selectivity in the Oxytocin‐Vasopressin Receptors

M. Manning, B. Mouillac, J. Hoflack, 1997 .

Cloning, expression and pharmacological characterization of a vasopressin-related receptor in an annelid, the leech Theromyzon tessulatum.

D. Vieau, B. Mouillac, A. Levoye, 2005, The Journal of endocrinology.

Leukotriene BLT2 Receptor Monomers Activate the Gi2 GTP-binding Protein More Efficiently than Dimers*

B. Mouillac, T. Durroux, S. Granier, 2009, The Journal of Biological Chemistry.